Cargando…
One dose of immunotherapy leading to an exceptional and durable response in a patient with metastatic renal cell carcinoma
A 72-year-old man with metastatic clear cell renal carcinoma, who had progressed after previous treatment with Sunitinib and Axitinib, was given one dose of immunotherapy. He was initially unwell after treatment with fever, shortness of breath, chest pain and raised inflammatory markers. Following t...
Autores principales: | Wade, Louise, Hilman, Serena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6937447/ https://www.ncbi.nlm.nih.gov/pubmed/31908826 http://dx.doi.org/10.1093/omcr/omz128 |
Ejemplares similares
-
Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma
por: Swofford, Brenen P., et al.
Publicado: (2017) -
Durable Remission with Immunotherapy in a Patient with Sarcomatoid Renal Cell Carcinoma
por: Nwabundo, Anusim, et al.
Publicado: (2021) -
Exceptional response to PD-1 inhibition immunotherapy in advanced metastatic osteosarcoma with tumor site infection
por: Li, Meng, et al.
Publicado: (2022) -
Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
por: Clark, Joseph I, et al.
Publicado: (2015) -
Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma
por: Tucker, Matthew D., et al.
Publicado: (2020)